Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
NCT04313322Phase 1Unknown
- Sponsor
- Stem Cells Arabia
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19), sponsored by Stem Cells Arabia. Primary endpoints: Clinical outcome at 3 weeks, Computed Tomography Scan at 3 weeks and 1 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04313322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313322.